Cost-effectiveness of a risk-based secondary screening programme of type 2 diabetes

Balázs Nagy, Adriána Zsólyom, László Nagyjánosi, Gergő Merész, Tamás Steiner, Eszter Papp, Zoltán Dessewffy, G. Jermendy, G. Winkler, Z. Kaló, Z. Vokó

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: The objective of this study was to develop a long-term economic model for type 2 diabetes to describe the entire spectrum of the disease over a wide range of healthcare programmes. The model evaluates a public health, risk-based screening programme in a country specific setting. Methods: The lifespan of persons and important phases of the disease and related interventions are recorded in a Markov model, which first simulates the effect of screening, then replicates important complications of diabetes, follows the progression of individuals through physiological variables and finally calculates outcomes in monetary and naturalistic units. Results: The introduction of the screening programme nearly doubled the proportion of diagnosed patients at the age of 50 and prolonged life expectancy. Three-yearly screening gained 0.0229 quality adjusted life years for an additional €83 per person compared with no screening and resulted an incremental cost-effectiveness ratio of €3630/quality adjusted life years. Conclusion: From the economic perspective introduction of the 3-yearly screening programme is justifiable and it provides a good value for money.

Original languageEnglish
Pages (from-to)710-729
Number of pages20
JournalDiabetes/Metabolism Research and Reviews
Volume32
Issue number7
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Quality-Adjusted Life Years
Type 2 Diabetes Mellitus
Cost-Benefit Analysis
Economic Models
Diabetes Complications
Life Expectancy
Public Health
Economics
Delivery of Health Care

Keywords

  • cost-effectiveness
  • diabetes
  • FINDRISC
  • model
  • patient level simulation
  • public health intervention
  • screening

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Cost-effectiveness of a risk-based secondary screening programme of type 2 diabetes. / Nagy, Balázs; Zsólyom, Adriána; Nagyjánosi, László; Merész, Gergő; Steiner, Tamás; Papp, Eszter; Dessewffy, Zoltán; Jermendy, G.; Winkler, G.; Kaló, Z.; Vokó, Z.

In: Diabetes/Metabolism Research and Reviews, Vol. 32, No. 7, 01.10.2016, p. 710-729.

Research output: Contribution to journalArticle

Nagy, Balázs ; Zsólyom, Adriána ; Nagyjánosi, László ; Merész, Gergő ; Steiner, Tamás ; Papp, Eszter ; Dessewffy, Zoltán ; Jermendy, G. ; Winkler, G. ; Kaló, Z. ; Vokó, Z. / Cost-effectiveness of a risk-based secondary screening programme of type 2 diabetes. In: Diabetes/Metabolism Research and Reviews. 2016 ; Vol. 32, No. 7. pp. 710-729.
@article{72583727c90e408cbeaf897678b28ec6,
title = "Cost-effectiveness of a risk-based secondary screening programme of type 2 diabetes",
abstract = "Objective: The objective of this study was to develop a long-term economic model for type 2 diabetes to describe the entire spectrum of the disease over a wide range of healthcare programmes. The model evaluates a public health, risk-based screening programme in a country specific setting. Methods: The lifespan of persons and important phases of the disease and related interventions are recorded in a Markov model, which first simulates the effect of screening, then replicates important complications of diabetes, follows the progression of individuals through physiological variables and finally calculates outcomes in monetary and naturalistic units. Results: The introduction of the screening programme nearly doubled the proportion of diagnosed patients at the age of 50 and prolonged life expectancy. Three-yearly screening gained 0.0229 quality adjusted life years for an additional €83 per person compared with no screening and resulted an incremental cost-effectiveness ratio of €3630/quality adjusted life years. Conclusion: From the economic perspective introduction of the 3-yearly screening programme is justifiable and it provides a good value for money.",
keywords = "cost-effectiveness, diabetes, FINDRISC, model, patient level simulation, public health intervention, screening",
author = "Bal{\'a}zs Nagy and Adri{\'a}na Zs{\'o}lyom and L{\'a}szl{\'o} Nagyj{\'a}nosi and Gergő Mer{\'e}sz and Tam{\'a}s Steiner and Eszter Papp and Zolt{\'a}n Dessewffy and G. Jermendy and G. Winkler and Z. Kal{\'o} and Z. Vok{\'o}",
year = "2016",
month = "10",
day = "1",
doi = "10.1002/dmrr.2791",
language = "English",
volume = "32",
pages = "710--729",
journal = "Diabetes/Metabolism Research and Reviews",
issn = "1520-7552",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Cost-effectiveness of a risk-based secondary screening programme of type 2 diabetes

AU - Nagy, Balázs

AU - Zsólyom, Adriána

AU - Nagyjánosi, László

AU - Merész, Gergő

AU - Steiner, Tamás

AU - Papp, Eszter

AU - Dessewffy, Zoltán

AU - Jermendy, G.

AU - Winkler, G.

AU - Kaló, Z.

AU - Vokó, Z.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Objective: The objective of this study was to develop a long-term economic model for type 2 diabetes to describe the entire spectrum of the disease over a wide range of healthcare programmes. The model evaluates a public health, risk-based screening programme in a country specific setting. Methods: The lifespan of persons and important phases of the disease and related interventions are recorded in a Markov model, which first simulates the effect of screening, then replicates important complications of diabetes, follows the progression of individuals through physiological variables and finally calculates outcomes in monetary and naturalistic units. Results: The introduction of the screening programme nearly doubled the proportion of diagnosed patients at the age of 50 and prolonged life expectancy. Three-yearly screening gained 0.0229 quality adjusted life years for an additional €83 per person compared with no screening and resulted an incremental cost-effectiveness ratio of €3630/quality adjusted life years. Conclusion: From the economic perspective introduction of the 3-yearly screening programme is justifiable and it provides a good value for money.

AB - Objective: The objective of this study was to develop a long-term economic model for type 2 diabetes to describe the entire spectrum of the disease over a wide range of healthcare programmes. The model evaluates a public health, risk-based screening programme in a country specific setting. Methods: The lifespan of persons and important phases of the disease and related interventions are recorded in a Markov model, which first simulates the effect of screening, then replicates important complications of diabetes, follows the progression of individuals through physiological variables and finally calculates outcomes in monetary and naturalistic units. Results: The introduction of the screening programme nearly doubled the proportion of diagnosed patients at the age of 50 and prolonged life expectancy. Three-yearly screening gained 0.0229 quality adjusted life years for an additional €83 per person compared with no screening and resulted an incremental cost-effectiveness ratio of €3630/quality adjusted life years. Conclusion: From the economic perspective introduction of the 3-yearly screening programme is justifiable and it provides a good value for money.

KW - cost-effectiveness

KW - diabetes

KW - FINDRISC

KW - model

KW - patient level simulation

KW - public health intervention

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=84989963629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989963629&partnerID=8YFLogxK

U2 - 10.1002/dmrr.2791

DO - 10.1002/dmrr.2791

M3 - Article

C2 - 26888326

AN - SCOPUS:84989963629

VL - 32

SP - 710

EP - 729

JO - Diabetes/Metabolism Research and Reviews

JF - Diabetes/Metabolism Research and Reviews

SN - 1520-7552

IS - 7

ER -